ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Friday, November 6, 2020

9:00AM-11:00AM: Abstract Number: 0142

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs: Results from the FINCH 2 Study

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0141

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results from FINCH-1 Study

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0143

Filgotinib Improved Work Productivity and Activity Impairment in Patients with Rheumatoid Arthritis Who Are Methotrexate-naïve: Results from the FINCH-3 Study

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0136

Filgotinib Significantly Improved Patient-reported Health-related Quality of Life for Patients with Active Rheumatoid Arthritis: A Post Hoc Analysis of SF-36 and HAQ-DI from Phase 3 Studies

Patient Outcomes, Preferences, & Attitudes Poster I: RA, Spondyloarthritis, & OA

9:00AM-11:00AM: Abstract Number: 0326

Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 0119

Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes

Osteoporosis & Metabolic Bone Disease Poster

9:00AM-11:00AM: Abstract Number: 0422

Frailty and Health-Related Quality of Life in Patients with Polymyalgia Rheumatica

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0067

Functionally Mature CD1c+ Dendritic Cells Contribute to Synovial Inflammation in Rheumatoid Arthritis via STAT3

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0267

Gastrointestinal Disease in SLE: Does It Indicate a Worse Prognosis?

SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

9:00AM-11:00AM: Abstract Number: 0034

Gene Expression Signatures in C-Reactive Protein High and Low Rheumatoid Arthritis

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0301

Genetic Associations and Polygenic Risk Assessment in Incomplete Lupus Erythematosus

SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0283

Genome-wide DNA Methylation Analysis in Lupus Keratinocytes Identifies Differential Methylation of Genes That Regulate Apoptosis

SLE – Etiology & Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 0086

Geographic Distribution of Eosinophilic Fasciitis Cases in Massachusetts and Associated Environmental Triggers

Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

9:00AM-11:00AM: Abstract Number: 0043

Geographical Disparity in Rheumatoid Arthritis Disease Burden Independent of Race/Ethnicity

Healthcare Disparities in Rheumatology Poster

9:00AM-11:00AM: Abstract Number: 0005

Geographical Variations in COVID-19 Perceptions and Patient Management: A National Survey of Rheumatologists

Epidemiology & Public Health Poster I: COVID-19 & Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].